The ingredients provided herein include packaging of anti-PD-L1 and anti-CTLA-4 antibody or antigen binding fragments and methods of manufacturing and using these ingredients. In several aspects, stable combinations of anti PD-L1 antibody of durvalumab (medi4736) and anti CTLA-4 antibody of tremelimumab are provided. 1. Characteristic 1: a component composed of durvalumab or a part of its antigen and tremelimumab, or a part of its antigen, or a part of its antigen, containing the concentration of durvalumab, or a part of its antigen,is from about 18.7 mg / mL to about 44.4 mg / mL and in which the concentration of tremelimumab, or an antigen-binding fragment thereof, is from about 2.2 mg / mL to about 12.5 mg / mL. Claim 17: A pharmaceutical composition comprising or consisting of approximately 44.4 mg / mL durvalumab, or an antibody fragment thereof, approximately 2.2 mg / mL tremelimumab, or an antibody fragment thereof, approximately 25 Histidine / Histidine-HCl mM, approximately 269 mM trehalose dehydrate, approximately 0.03 mM EDTA and approximately 0.02% w / v PS80 at a pH of approximately 6.0.Se proporcionan aquí composiciones que comprenden la coformulación de anticuerpos anti-PD-L1 y anti-CTLA-4, o fragmentos de unión a antígeno de los mismos, y métodos para fabricar y usar tales composiciones. En diversos aspectos, se proporcionan coformulaciones estables del anticuerpo anti-PD-L1 durvalumab (MEDI4736) y el anticuerpo anti-CTLA-4 tremelimumab. Reivindicación 1: Una composición que comprende durvalumab, o un fragmento de unión a antígeno del mismo, y tremelimumab, o un fragmento de unión a antígeno del mismo, en el que la concentración de durvalumab, o un fragmento de unión a antígeno del mismo, es de aproximadamente 18,7 mg/mL a aproximadamente 44,4 mg/mL y en el que la concentración de tremelimumab, o un fragmento de unión a antígeno del mismo, es de aproximadamente 2,2 mg/mL a aproximadamente 12,5 mg/mL. Reivindicación 17: Una composición farmacéutica qu
